Ibrahim N Muhsen
Overview
Explore the profile of Ibrahim N Muhsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hendricks C, Spadea M, Du Toit J, Gurnari C, Muratori R, Jimenez V, et al.
Lancet Haematol
. 2025 Mar;
12(3):e178-e179.
PMID: 40044255
No abstract available.
2.
Roloff G, Aldoss I, Kopmar N, Lin C, Dekker S, Gupta V, et al.
J Clin Oncol
. 2024 Oct;
43(5):558-566.
PMID: 39418622
Purpose: On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October...
3.
Muhsen I, Shaver K, Wang T, Wu M, Lulla P, Ramos C, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1193.e1-1193.e8.
PMID: 39277112
In vivo T-cell depletion (TCD) using alemtuzumab decreases the risk of Graft vs Host Disease (GvHD) in recipients of allogeneic hematopoietic stem cell transplant (allo-HSCT). However, this approach increases the...
4.
Aldoss I, Roloff G, Faramand R, Kopmar N, Lin C, Advani A, et al.
Blood Adv
. 2024 Aug;
8(23):6139-6147.
PMID: 39093952
The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189...
5.
Muhsen I, Zubair A, Niederwieser T, Hashmi S
Leukemia
. 2024 Jul;
38(9):1872-1875.
PMID: 38969730
No abstract available.
6.
Muhsen I, Heslop H
Br J Haematol
. 2024 Jun;
205(2):406-408.
PMID: 38895787
Immune response to vaccinations is dampened in patients with indolent lymphomas due to disease and treatment-related factors. The study by Lim et al. demonstrated impaired humoral response but intact cellular...
7.
Jamison T, Haque E, Muhsen I, Samarkandi H, El Fakih R, Aljurf M
Med Oncol
. 2024 Jun;
41(7):177.
PMID: 38884819
Treating metastatic malignancies to the central nervous system (CNS) is challenging because many drugs cannot cross the blood-brain-barrier (BBB). Direct intrathecal (IT) drug administration into the cerebrospinal fluid (CSF) is...
8.
Mushtaq A, Shafqat A, Salah H, Hashmi S, Muhsen I
Curr Opin Oncol
. 2023 Oct;
35(6):594-600.
PMID: 37820094
Purpose Of Review: This review delves into the potential of artificial intelligence (AI), particularly machine learning (ML), in enhancing graft-versus-host disease (GVHD) risk assessment, diagnosis, and personalized treatment. Recent Findings:...
9.
Haque E, Muhsen I, Rasheed W, El Fakih R, Aljurf M
Transpl Infect Dis
. 2023 Oct;
25 Suppl 1:e14160.
PMID: 37793057
Introduction: Hematopoietic stem cell transplantation (HSCT) is a vital treatment for various hematological disorders. However, HSCT recipients face increased risks of infectious complications due to immunosuppression. Parasitic infections are a...
10.
Yang E, Muhsen I, Samarkandi H, El Fakih R, Aljurf M, Hanbali A
Hematol Oncol Stem Cell Ther
. 2023 Aug;
17(1):4-12.
PMID: 37581463
Daratumumab is a first-in-class human anti-CD38 IgG1 monoclonal antibody approved for treating newly diagnosed and relapsed refractory multiple myeloma. Pre-clinical data supported daratumumab's ability to deplete autoantibodies producing plasma cells,...